Natalizumab (subcutaneous injection) for highly active relapsing remitting multiple sclerosis

featured image
Therapeutic Areas: Neurology
Year: 2021

Natulizumab administered as a subcutaneous formulation is currently in clinical development for highly active relapsing remitting multiple sclerosis (RRMS). RRMS is characterised by periods of exacerbation of symptoms (relapses) followed by unpredictable periods of stability (remission). Highly active disease is characterised by an unchanged/increased relapse rate or by ongoing severe relapses compared with the previous year. Natalizumab is currently administered intravenously for patients with multiple sclerosis, however subcutaneous natalizumab injections require less time and are easier to perform.

Natalizumab is a type of biologic drug which binds to immune cells in the blood stream, preventing them from passing from the blood into the central nervous system where they can damage nerves. If licensed, subcutaneous natalizumab will offer more convenient treatment option for patients with highly active RRMS.